Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — 1mg is not a starting dose for Wegovy. The licensed schedule begins at 0.25mg once weekly, and 1mg sits mid-way through a step-by-step titration that your prescriber controls. Jumping straight to 1mg is outside the approved UK schedule and increases the risk of side effects without improving results. Semaglutide (the active medicine in Wegovy) is a prescription-only treatment in the UK, which means a GPhC-registered prescriber must assess your suitability and guide your dose, pen by pen.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a reasonable question. You know 2.4mg is the maintenance target, so 1mg sounds like a sensible middle-ground entry point, not too cautious, not too aggressive. The problem is that the licensed UK schedule isn't designed around convenience; it's designed around how your gut adapts to semaglutide.
Wegovy works by activating GLP-1 receptors involved in appetite signalling and gastric emptying. At higher doses it powerfully slows how quickly your stomach empties, which is exactly what reduces appetite and drives weight loss, but it also causes the nausea and digestive upset that most people experience at the start. The titration schedule exists so your body has time to adjust at each level before the dose climbs again. Starting at 1mg skips the two steps that do most of that adjustment work. The NHS semaglutide medicines page sets out the full sequence and why it matters.
At 1mg your system hasn't been primed. The GI effects can hit hard, and some people drop out of treatment entirely because the early weeks feel unmanageable, not because the medicine doesn't suit them, but because the start was too steep. The 0.25mg and 0.5mg steps aren't just formalities. They matter.
The schedule your prescriber follows looks like this: 0.25mg for the first four weeks, 0.5mg for the next four weeks, then 1mg) and at that point you're already three months in. From 1mg the path continues through 1.7mg and then 2.4mg, the standard maintenance dose.
Crucially, those four-week periods are minimums, not deadlines. If nausea or vomiting is still difficult at 0.5mg after four weeks, a prescriber can hold you there rather than moving up. That flexibility is the point of clinical oversight. The dose schedule is also why the full Wegovy dose range spans five steps rather than two or three, not because of pharmaceutical convention, but because trial data showed that slower titration meant more people could reach and stay at the maintenance dose.
What happens if you somehow obtain 1mg pens and use them as a starting dose? You'd be taking a prescription medicine outside its licensed schedule. That alone should give pause; it also means there's no prescriber monitoring the side effects you experience, and no clinical record to draw on if something needs adjusting. For context on what genuine access looks like, how to get Wegovy from a legitimate UK pharmacy is worth reading before you start.
A common frustration people share: the starter pen arrives, you inject it, and nothing obvious changes. Weight doesn't shift. Appetite feels similar. It can seem like the medicine isn't working.
That first pen's job is settling your system, not treating. At 0.25mg the appetite-regulating effects are subtle; the dose is calibrated so your GI tract gets its first exposure to semaglutide without the full force of the higher levels. Weeks three and four at this dose often feel noticeably different from week one, the adjustment is gradual rather than instant. The clinical evidence underpinning this approach is solid: the STEP 1 trial, published in the New England Journal of Medicine, followed the same titration protocol across nearly 2,000 adults and reported approximately 15% average body-weight reduction at 2.4mg over 68 weeks. The titration was part of the design, not an inconvenience around it.
If you're looking at whether you can begin at 2.4mg or wondering about jumping straight to 0.5mg, the answer follows the same logic: starting above 0.25mg isn't the licensed route, and the reasons for that are grounded in patient safety rather than bureaucracy. Questions about cost or what a private prescription includes are addressed on our treatment page.
One practical note: when your first Wegovy pen arrives, it comes in plain, unbranded packaging via DPD with a tracking link, usually the next working day if your prescription is approved before midday. The pen itself is pre-filled and single-use; each contains four doses. Your prescriber's instructions travel with it. That's also when the real process begins, not when you press confirm, but when a clinician reads your consultation and decides the dose that's right for your circumstances.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.